Author Archives: Julian Upton

NICE's Tarceva Decision "Perverse", Says Roche

The UK National Institute for Health and Care Excellence’s (NICE) decision that relapsed non-small cell lung cancer patients should no longer have access to Roche’s cancer pill Tarceva (erlotinib) is a setback for lung cancer care in England and Wales, where “over 1,000 patients a year will be left without an active treatment option after […]
Posted in pricing, Regulatory | Tagged , , , , , | Leave a comment

BRIC Opportunities 2014

While the tide has been turning for pharma in the BRIC markets, they will continue to be important but only if the industry has learnt the hard lessons of the last few years. Speaking to Pharm Exec for the 2014 Industry Outlook, Reenita Das, Partner at Frost & Sullivan, says its now more important than […]
Posted in Global, Strategy | Tagged , , , , , , , , | Leave a comment

Europe's IMI Looks to Portugal and Finland to Lead Scientific Committee

Europe’s Innovation Medicines Initiative (IMI) has appointed experts from Portugal and Finland to chair the IMI Scientific Committee. Professor Maria Beatriz da Silva Lima of the University of Lisbon in Portugal will be the new Chair; Professor Markus Perola of Finland’s National Institute for Health and Welfare was appointed Vice Chair. The IMI is the […]
Posted in Europe, Global | Tagged , , , , | Leave a comment

Big Pharma's "Firepower" Effectively Dropped by 20% in 2013, Says Report

Although Big Pharma’s ‘firepower’ increased last year by $100 billion, it declined in comparison with that of Big Biotech and specialty pharma, according to a new report from EY. EY’s Firepower Index measures companies’ capacity for conducting M&A deals. Firepower is diminished as its market value, cash and equivalents fall or as its debt levels […]
Posted in Strategy | Tagged , , , , | Leave a comment

EU Clinical Trials Agreement 'Compromised', Says Industry

European Union (EU) regulators reached agreement today on the much-vaunted Clinical Trials Regulation. The regulation harmonizes the rules for the conduct of clinical trials in the EU and the ‘acceptability’ of the resulting data, and palces further safeguards on the safety of trial subjects. The legislation’s aim is to facilitate and expedite the authorization procedure […]
Posted in Europe, Global, R&D, Regulatory | Tagged , , , , | Leave a comment
  • Categories

  • Meta